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Lobular carcinoma in situ of the breast (LCIS) is a relatively rare
disease (incidence rate: in Europe 9/100 000, USA between 15 and
17/100 000) (Levi et al, 1997) with a distinctive histological
appearance characterized by masses of loosely arranged cells with
round, monotonous hyperchromatic nuclei that distend acini of the
lobular unit. Mitoses, necrosis and cellular anaplasia are usually
absent (Foote et al, 1941; Frykberg et al, 1987; Beute et al, 1991).
In contrast to ductal carcinoma in situ (DCIS), the disease is often
multicentric within one breast, and in half or more cases is bilat-
eral (Ottesen et al, 1993; Millikan et al, 1995). Over 80% of
patients with LCIS are diagnosed between 40 and 50 years of age,
usually as an incidental finding in a biopsy taken for other
palpable or mammography-detected benign or malignant lesions
(Bartow et al, 1987; Frykberg et al, 1987; Beute et al, 1991).
LCIS confers an elevated risk of invasive cancer. Over the 25
years following diagnosis, approximately one-fifth of LCIS cases
will develop invasive cancer. Many of these occur in young women,
and the risk of breast cancer in LCIS is increased tenfold (Page et al,
1991; Ottesen et al, 1993; Milikan et al, 1995). Invasive cancers are
equally likely to occur in the contralateral breast as in the breast
known to carry LCIS (Millikan et al, 1995). This is in contrast to
partially resected DCIS in which the invasive cancer usually
develops in the same quadrant of the same breast. Approximately
half of invasive cancers developing upon a background of LCIS are
lobular in histological type, the remainder being a mixture of ductal,
tubular and others (Page et al, 1991; Ottesen et al, 1993).
The biological nature of LCIS and its relationship to invasive
cancers is controversial. The multicentricity of the disease has led
some authors to propose that it is a hyperplastic rather than a
neoplastic process. Some authorities regard LCIS as a risk indi-
cator for invasive cancer or a morphological marker of a carcino-
genic stimulus, and do not believe that the cancer itself arises from
the abnormal LCIS cells. An alternate view, which is generally
accepted for DCIS, is that LCIS cells are intermediates in the
progression to invasive cancer.
The pattern of early age of onset and multicentricity of neoplasms
is reminiscent of heritable cancer predisposition syndromes, and
suggests that LCIS may result from an inherited susceptibility. This
hypothesis is supported by data showing that foci of LCIS are likely
to be clonal (Lakhani et al, 1995). Furthermore, there is evidence
from systematic studies that both LCIS and invasive lobular carci-
noma are associated with higher familial risks of breast cancer than
other histological types (Claus et al, 1993; Cannon-Albright et al,
1994). LCIS is not a manifestation of BRCA1 or BRCA2 mutations
(BCLC, 1997) and therefore may be an indicator of a previously
unrecognized cancer predisposition syndrome, in which the pene-
trance for invasive cancer is relatively low.
There are no known genes that confer susceptibility to LCIS.
However, there is a-priori evidence suggesting that E-cadherin is a
strong candidate for an LCIS predisposition gene. E-cadherin is a
transmembrane adhesion protein with a central role in the mainte-
nance of the normal architecture and function of epithelial cells
(Takeichi, 1995). Over 400 tumours from ten different tissue types
have been screened for E-cadherin mutations (Berx et al, 1998).
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Summary Lobular carcinoma in situ (LCIS) is an unusual histological pattern of non-invasive neoplastic disease of the breast occurring
predominantly in women aged between 40 and 50 years. LCIS is frequently multicentric and bilateral, and there is evidence that it is
associated with an elevated familial risk of breast cancer. Although women with LCIS suffer an increased risk of invasive breast disease, this
risk is moderate suggesting that LCIS may result from mutation of a gene or genes conferring a high risk of LCIS, but a lower risk of invasive
breast cancer. The high frequency of somatic mutations in E-cadherin in LCIS, coupled with recent reports that germline mutations in this
gene can predispose to diffuse gastric cancer, raised the possibility that constitutional E-cadherin mutations may confer susceptibility to LCIS.
In order to explore this possibility we have examined a series of 65 LCIS patients for germline E-cadherin mutations. Four polymorphisms
were detected but no pathogenic mutations were identified. The results indicate that E-cadherin is unlikely to act as a susceptibility gene for
LCIS. © 2000 Cancer Research Campaign
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DOI: 10.1054/ bjoc.1999.0965, available online at http://www.idealibrary.com on Somatic mutations occur frequently in two histological subtypes:
diffuse gastric carcinomas and lobular breast cancers. In lobular
breast carcinomas, the E-cadherin mutations generally result in
premature truncation of translation and are usually accompanied
by loss of the wild-type allele (Berx et al, 1995, 1996). This
suggests that E-cadherin acts as a tumour suppressor gene. In
LCIS, E-cadherin expression is almost always absent (Moll et al,
1993), and somatic E-cadherin mutations together with loss of
heterozygosity (LOH) of the wild-type allele have been identified
(Vos et al, 1997). In two breast cancers, the same mutation was
identified in the LCIS and invasive components, supporting the
theory that LCIS is an invasive precursor (Vos et al, 1997). In
contrast, somatic E-cadherin mutations have not been reported in
either DCIS or invasive ductal breast carcinomas and E-cadherin
expression is not absent in these neoplasms (Vos et al, 1997; Berx
et al, 1998). Loss of E-cadherin has been demonstrated in LCIS
adjacent to E-cadherin-positive invasive lobular cancers (de
Leeuw et al, 1997) indicating that loss of E-cadherin is an
important early step in the formation of LCIS. To our knowledge,
the presence of constitutional E-cadherin mutations in individuals
with LCIS has not been investigated. However, constitutional E-
cadherin mutations that predispose to familial diffuse gastric
cancer have been identified (Gayther et al, 1998; Guilford et al,
1998). In order to examine whether constitutional alterations in E-
cadherin predispose to LCIS we have analysed blood samples
from 65 patients with LCIS for germline mutations in the gene.
PATIENTS AND METHODS
Patients
All individuals with a histologically proven diagnosis of LCIS that
attended the Royal Marsden Hospital between 1971 and 1996 were
invited to participate. Samples were obtained with informed
consent and local ethical review board approval. EDTA-venous
blood samples were obtained from 65 patients. DNA was extracted
using a standard sucrose lysis protocol.
Methods
The full coding sequence and splice junctions of E-cadherin were
screened for mutations using conformational specific gel
electrophoresis (CSGE) (Ganguly et al, 1993). Published oligo-
nucleotide sequences were used to amplify each exon of the E-
cadherin gene (including splice sites) by polymerase chain
reaction (PCR) (Berx et al, 1995). All samples with bandshifts
detected by CSGE were sequenced in duplicate and in forward and
reverse orientations after re-amplification of the appropriate exon
from genomic DNA in the PCR. Purified PCR products were
sequenced using ABI Ready Reaction Dye Terminator Cycle
Sequencing Kit and the ABI 377 Prism sequencer.
RESULTS
DNA from 65 patients with a histologically proven diagnosis of
LCIS was obtained. None of the patients had invasive cancer at the
time of diagnosis of LCIS. The clinical details of the patients are
shown in Table 1. Seventeen of the patients had bilateral disease
and 21 also had a diagnosis of DCIS. Twenty of the patients had a
first-degree relative affected with invasive breast cancer, but only
one had a family history highly suggestive of the inheritance of a
dominantly acting breast cancer susceptibility gene.
The full coding sequence and splice junctions of E-cadherin
were screened for mutations in all samples. No pathogenic muta-
tions were identified in any of the patients screened. Four poly-
morphic variants were detected in 29 of the patients (Table 2). All
were synonymous substitutions and have been previously reported
(Berx et al, 1998).
DISCUSSION
We have obtained DNA from 65 individuals with LCIS. Thirty-
two per cent of the patients studied had a family history of invasive
breast cancer suggesting that LCIS confers a fourfold increase in
breast cancer risk in first-degree relatives. Twenty-six per cent of
patients had bilateral disease. These data are concordant with the
hypothesis that a proportion of LCIS results from inherited
predisposition and suggests that a LCIS susceptibility gene may
also confer an elevated risk of invasive breast cancer.
E-cadherin is mutated somatically at high frequency in LCIS,
invasive lobular breast cancer and diffuse gastric cancer (Berx et al,
1998). Constitutional predisposing E-cadherin mutations have
recently been detected in familial gastric cancer pedigrees (Gayther
et al, 1998; Guildford et al, 1998). We have examined lymphocyte
DNA from 65 individuals with LCIS, for germline alterations in 
E-cadherin. No disease-causing alterations were identified. This
suggests that constitutional mutations in E-cadherin do not confer
susceptibility to LCIS.
We cannot exclude the possibility that a minority of mutations
have been missed, or cannot be detected by a PCR-based
approach. However, under test conditions we have found this tech-
nique can detect all small insertions and deletions and 90% of
single-base substitutions. Confirmation of the efficiency of this
technique is that we were able to demonstrate a number of single-
base substitution polymorphisms within the gene. Therefore it is
unlikely that we have failed to detect any coding mutations.
It is theoretically possible that constitutive mutations in E-
cadherin are responsible for a few LCIS cases. However, based on
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Table 1 Ages and clinical characteristics of the 65 patients with LCIS
Age (years)
Mean (± s.d.) 48 (7.7)
Range 26–71
Breast disease
Bilateral LCIS 17/65 (26%)
Co-existing DCIS 21/65 (32%)
Family history of breast cancer
Affected first-degree relative 20/65 (31%)
Dominant pedigree 1/65 (2%)
Table 2 Summary of E-cadherin gene variations detected
No. of Codon no. Amplicon Polymorphism
patients
1 115 Exon 3 ACG (Thr) to ACA (Thr)
4 632 Exon 12 CAC (His) to CAT (His)
28 692 Exon 13 GCC (Ala) to GCT (Ala)
2 751 Exon 14 AAC (Asn) to AAT (Asn)570 N Rahman et al
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the number of patients we have examined we can conclude with
95% probability that germline variation in E-cadherin does not
account for more than 4% of cases of LCIS.
The high frequency of somatic mutations in the E-cadherin gene
in LCIS coupled with the recent finding that germline mutations in
the gene can predispose to diffuse gastric cancer suggested that
constitutional E-cadherin mutations might confer susceptibility to
LCIS. The results presented indicate that this is very unlikely and
that the majority of LCIS cases do not result from germline muta-
tions in E-cadherin. However, the elevated incidence of bilateral
LCIS and of invasive breast cancer in relatives, supports the
hypothesis that a proportion of LCIS results from genetic suscepti-
bility. The identity of this susceptibility gene is unknown, but may
also be a low penetrance invasive breast cancer susceptibility
gene.
Note added in proof
A frameshift mutation in exon 3 of E-cadherin has recently been
reported in a patient with LCIS who had a strong family history of
gastric cancer (Keller et al, 1999).
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